Silence Therapeutics Q2 Loss Narrows to $12.3M; Cash Runway Extended into 2028

summarizeSummary

Silence Therapeutics' Q2 2026 loss narrowed sharply to $12.3M, cash rose to $72.1M extending runway into 2028, and the pivotal Phase 2 divesiran trial completed dosing with data imminent.

check_boxKey Events · Earnings and Guidance · SLN

• Q2 Loss Narrows Significantly

  Net loss of $12.3M vs. $27.4M in Q2 2025, driven by a $8.5M reduction in R&D costs as zerlasiran Phase 3 readiness activities concluded.

• Cash Runway Extended into 2028

  Cash and equivalents rose to $72.1M at June 30, 2026, from $11.3M at year-end 2025, primarily from maturing U.S. Treasury bills. Management expects this to fund operations into 2028.

• Divesiran Phase 2 Dosing Complete

  The SANRECO Phase 2 trial in polycythemia vera completed patient dosing in June 2026; topline results are anticipated in August 2026, representing a near-term catalyst.

• ATM Program Untapped in Q2

  No shares were sold under the $100 million at-the-market offering program during the quarter, reducing immediate dilution overhang.

auto_awesomeAnalysis · SLN · Life Sciences

A sharply narrower Q2 net loss of $12.3 million, compared with $27.4 million a year ago, reflects reduced R&D spending after Silence Therapeutics completed Phase 3 readiness for zerlasiran. Cash jumped to $72.1 million from $11.3 million at year-end, largely from maturing short-term investments, extending the runway into 2028. The Phase 2 SANRECO trial for lead asset divesiran in polycythemia vera completed dosing, with topline data due this month — a near-term catalyst. No shares were sold under the $100 million ATM program during the quarter, easing immediate dilution concerns. The filing also disclosed a separation agreement with the former CEO, modifying unvested option terms in a change-of-control scenario.